These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22269933)

  • 41. Influence of cultivation conditions on spatial structure and functional activity of OmpF-like porin from outer membrane of Yersinia pseudotuberculosis.
    Novikova OD; Vakorina TI; Khomenko VA; Likhatskaya GN; Kim NY; Emelyanenko VI; Kuznetsova SM; Solov'eva TF
    Biochemistry (Mosc); 2008 Feb; 73(2):139-48. PubMed ID: 18298369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Study of effect of substitution of the penultimate amino acid residue on expression, structure, and functional properties of Yersinia pseudotuberculosis OmpY porin.
    Solov'eva TF; Tischenko NM; Khomenko VA; Portnyagina OY; Kim NY; Likhatskaya GN; Novikova OD; Isaeva MP
    Biochemistry (Mosc); 2014 Jul; 79(7):694-705. PubMed ID: 25108332
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salmonella porins induce a sustained, lifelong specific bactericidal antibody memory response.
    Secundino I; López-Macías C; Cervantes-Barragán L; Gil-Cruz C; Ríos-Sarabia N; Pastelin-Palacios R; Villasis-Keever MA; Becker I; Puente JL; Calva E; Isibasi A
    Immunology; 2006 Jan; 117(1):59-70. PubMed ID: 16423041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-pathogenic Borrelia burgdorferi expressing Treponema pallidum TprK and Tp0435 antigens as a novel approach to evaluate syphilis vaccine candidates.
    Parveen N; Fernandez MC; Haynes AM; Zhang RL; Godornes BC; Centurion-Lara A; Giacani L
    Vaccine; 2019 Mar; 37(13):1807-1818. PubMed ID: 30797635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of a lipopolysaccharide on the conformational state and functional activity of a Yersinia pseudotuberculosis porin].
    Novikova OD; Kim NIu; Glazunov VP; Vakorina TI; Naberezhnykh GA; Likhatskaia GN; Khomenko VA; Solov'eva TF
    Bioorg Khim; 1999 Feb; 25(2):97-106. PubMed ID: 10495899
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Formation of Amyloid-Like Conformational States of β-Structured Membrane Proteins on the Example of OMPF Porin from the
    Novikova OD; Rybinskaya TV; Zelepuga EA; Uversky VN; Kim NY; Chingizova EA; Menchinskaya ES; Khomenko VA; Chistyulin DK; Portnyagina OY
    Biochemistry (Mosc); 2024 Jun; 89(6):1079-1093. PubMed ID: 38981702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biological activity of bacterial cell-wall components: immunogenicity of the bacterial extract OM-89.
    Sedelmeier EA; Bessler WG
    Immunopharmacology; 1995 Feb; 29(1):29-36. PubMed ID: 7768669
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
    Singh M; Ganguly NK; Kumar L; Vohra H
    Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Th1 and Th2 cell involvement in immune response to Salmonella typhimurium porins.
    Galdiero M; De Martino L; Marcatili A; Nuzzo I; Vitiello M; Cipollaro de l'Ero G
    Immunology; 1998 May; 94(1):5-13. PubMed ID: 9708180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan-functionalized gold nanoparticles and botanical adjuvant: characterization, immunogenicity, and stability assessment.
    Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V
    J Pharm Sci; 2014 Nov; 103(11):3448-3456. PubMed ID: 25219511
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two new monogalactosyl diacylglycerols from brown alga Sargassum thunbergii.
    Kim YH; Kim EH; Lee C; Kim MH; Rho JR
    Lipids; 2007 Apr; 42(4):395-9. PubMed ID: 17406933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
    Hadad R; Marks E; Kalbina I; Schön K; Unemo M; Lycke N; Strid Å; Andersson S
    APMIS; 2016 Dec; 124(12):1078-1086. PubMed ID: 27859689
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.
    Cheng C; Jain P; Bettahi I; Pal S; Tifrea D; de la Maza LM
    Vaccine; 2011 Sep; 29(38):6641-9. PubMed ID: 21742006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of adjuvant composition on immune response to a multiple antigen peptide (MAP) containing a protective epitope from Neisseria meningitidis class 1 porin.
    Christodoulides M; Rattue E; Heckels JE
    Vaccine; 1999 Aug; 18(1-2):131-9. PubMed ID: 10501243
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IgG Responses to Porins and Lipopolysaccharide within an Outer Membrane-Based Vaccine against Nontyphoidal
    Schager AE; Dominguez-Medina CC; Necchi F; Micoli F; Goh YS; Goodall M; Flores-Langarica A; Bobat S; Cook CNL; Arcuri M; Marini A; King LDW; Morris FC; Anderson G; Toellner KM; Henderson IR; López-Macías C; MacLennan CA; Cunningham AF
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Immunochemical characteristics of synthetic peptides incorporating T- and B-cell epitopes nonspecific porins of pathogenic Yersinia].
    Portniagina OIu; Sidorova OV; Novikova OD; Vostrikova OP; Khomenko VA; Solov'eva TF
    Bioorg Khim; 2010; 36(6):779-88. PubMed ID: 21317944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of immune responses to gonococcal PorB delivered as outer membrane vesicles, recombinant protein, or Venezuelan equine encephalitis virus replicon particles.
    Zhu W; Thomas CE; Chen CJ; Van Dam CN; Johnston RE; Davis NL; Sparling PF
    Infect Immun; 2005 Nov; 73(11):7558-68. PubMed ID: 16239559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.
    Vasquez AE; Manzo RA; Soto DA; Barrientos MJ; Maldonado AE; Mosqueira M; Avila A; Touma J; Bruce E; Harris PR; Venegas A
    Hum Vaccin Immunother; 2015; 11(3):776-88. PubMed ID: 25750999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.